Olmesartan Medoxomilo Ciclum

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo Ciclum, is a Angiotensin II receptor blocker (ARBs) presented as a strength/form for oral use. It treats hypertension and may be used in adults requiring blood pressure control. GNH USA supplies Olmesartan Medoxomilo Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomilo Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes.

Olmesartan medoxil may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Upper respiratory infection

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Myocardial infarction (rare)

When prescribing olmesartan medoxil, clinicians should consider several safety aspects.

- Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium, especially if combined with potassium‑sparing agents. - Pregnancy: contraindicated in the second and third trimesters. - Elderly patients: start at lower dose and monitor for hypotension. - Drug interactions: review concomitant medications for additive blood‑pressure effects. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan medoxil can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients may increase risk of renal impairment. - Potassium‑rich supplements: may cause dangerous hyper‑kalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Diuretics: may enhance hypotensive response. - Lithium: may increase lithium levels. - ACE inhibitors: concurrent use can increase risk of angio‑edema. - CYP450 inducers: may reduce plasma concentration of olmeset.